Compass Pathways completed its NDA for COMP360 based on 2 phase 3 trials and a phase 2b study with more than 1000 participants with highly chronic TRD.
News|Articles|March 13, 2024
COVID-19 Never Truly Goes Away: Long COVID’s Debilitating Symptoms Uproots Lives
Author(s)Chelsie Derman
Now, 4 years since the start of the pandemic, how has sleep been impacted? Sleep experts provide their perspective.
Advertisement
Advertisement
Before Liza Fisher contracted the COVID-19 virus, she worked as a flight attendant, drove, and went to the grocery store with ease. All that came to a halt after the virus entered her body in early 2020. Like many others, she was quarantined, unable to see friends or family.
Related to this article
A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.
Oral icotrokinra beat placebo and was noninferior to ustekinumab in moderate to severe plaque psoriasis in the phase 3 ICONIC-ASCEND trial.
HIBISCUS showed a 48.7% vs 7.2% hemoglobin response at week 24, with an FDA decision expected in 2027.
Experts outline when to stop cycling topical steroids in chronic hand eczema and where topical delgocitinib now fits.
TRANSCEND-T2D-2 topline data show retatrutide lowered A1C more and produced over twice the weight loss of semaglutide 2 mg in type 2 diabetes.
Tom Martens, MD, joins Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss CONNECT trial data on CGM in non-insulin-treated type 2 diabetes.
Leigh Ann Pansch, MSN, FNP-BC, DCNP, discusses year-round photoprotection, missed skin cancer detection, and overlooked patients for Healthy Skin Month.
Advertisement
Advertisement